[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].

Abstract

A 74-year-old female with relapsed multiple myeloma was treated with twice-weekly bortezomib plus dexamethasone (BD)therapy, but severe gastrointestinal adverse events(grade 3 paralytic ileus and constipation)developed. After changing to once-weekly BD therapy, ≥ grade 3 gastrointestinal adverse events did not develop, and she was able to continue BD therapy. A complete response and a treatment-free interval ≥ 2 years were obtained by 8 courses of BD therapy. This case report suggests that once-weekly BD therapy may reduce severe gastrointestinal adverse events without decreasing the clinical efficacy for multiple myeloma.

• Authors: Toshihiro Fukushima, Haruka Iwao, Tomoyuki Sakai, Tomomi Sato, Takuji Nakamura, Akio Nakajima, Miyuki Miki, Toshioki Sawaki, Yoshimasa Fujita, Masao Tanaka, Yasufumi Masaki, Hisanori Umehara
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 5 Pg. 805-7 (May 2012) ISSN: 0385-0684 [Print] Japan
• PMID: 22584336 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Boronic Acids
• Pyrazines
• Bortezomib
• Dexamethasone

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Boronic Acids (administration & dosage, adverse effects)
• Bortezomib
• Constipation (chemically induced)
• Dexamethasone (administration & dosage, adverse effects)
• Female
• Humans
• Intestinal Pseudo-Obstruction (chemically induced)
• Multiple Myeloma (drug therapy, pathology)
• Neoplasm Staging
• Pyrazines (administration & dosage, adverse effects)
• Recurrence